A Phase 3b, double-blind, randomised, placebo-controlled study, known as STRIDE, investigating semaglutide for walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes, was published on 2025-01-01. The study compared semaglutide against placebo in this specific patient population.
Background
This study focused on semaglutide, a medication being investigated for its potential effects on walking capacity. The trial specifically targeted individuals diagnosed with symptomatic peripheral artery disease and type 2 diabetes. Peripheral artery disease (PAD) is a common circulatory problem where narrowed arteries reduce blood flow to the limbs, often causing leg pain when walking, known as claudication. Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose), and it is a significant risk factor for PAD.
Trial design
The STRIDE study was designed as a Phase 3b, double-blind, randomised, placebo-controlled trial. Its primary objective was to compare the effects of semaglutide against a placebo. The study population included people with symptomatic peripheral artery disease and type 2 diabetes, aiming to assess the impact of the drug on their walking capacity. The double-blind nature of the study ensures that neither the participants nor the researchers knew who was receiving the active drug versus the placebo, minimizing bias.
What this means
The publication of the STRIDE study indicates a continued effort to explore the therapeutic potential of semaglutide beyond its established uses, specifically addressing a significant unmet need in patients with symptomatic peripheral artery disease and type 2 diabetes. Walking capacity is a critical measure of functional independence and quality of life for individuals with PAD. Understanding how semaglutide might influence this outcome could have important implications for managing these complex comorbidities. Clinicians and researchers will be able to review the full findings to understand the specific results regarding walking capacity in this patient group.
Source
The information regarding this study was published on 2025-01-01 in The Lancet, and referenced by PubMed. The publication is titled "Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placeb" and is available via pubmed.ncbi.nlm.nih.gov.